NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 05/22/2026
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5.14 mln
Float2.46 mln
Earnings Date05/12/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-2.3
Borderline
Relative Strength
100
/ 100
Top performer
Debt / Equity
0.06
Debt-free
ROE
-87.67
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
InMed Pharmaceuticals is a Canadian drug development company focused on creating medicines derived from rare cannabinoids, operating both a research division and a commercial manufacturing business. Its most advanced drug candidate is a topical cream called INM-755, designed to treat a rare and painful skin condition called epidermolysis bullosa, which has already completed a Phase 2 clinical trial. The company is also working on treatments for eye disease, Alzheimer's, and other neurological conditions, while its commercial arm supplies rare cannabinoid ingredients to the broader health and wellness market.
